Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer.

Shaik T, Rather GM, Bansal N, Minko T, Garbuzenko O, Szekely Z, Abali EE, Banerjee D, Kerrigan JE, Scotto KW, Bertino JR.

Oncotarget. 2018 Sep 7;9(70):33249-33257. doi: 10.18632/oncotarget.26064. eCollection 2018 Sep 7.

2.

Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.

Newman JH, Augeri DJ, NeMoyer R, Malhotra J, Langenfeld E, Chesson CB, Dobias NS, Lee MJ, Tarabichi S, Jhawar SR, Bommareddy PK, Marshall S, Sadimin ET, Kerrigan JE, Goedken M, Minerowicz C, Jabbour SK, Li S, Carayannopolous MO, Zloza A, Langenfeld J.

Oncogene. 2018 Jul;37(27):3672-3685. doi: 10.1038/s41388-018-0156-9. Epub 2018 Apr 6.

PMID:
29622797
3.

Tumor stroma interaction is mediated by monocarboxylate metabolism.

Patel BB, Ackerstaff E, Serganova IS, Kerrigan JE, Blasberg RG, Koutcher JA, Banerjee D.

Exp Cell Res. 2017 Mar 1;352(1):20-33. doi: 10.1016/j.yexcr.2017.01.013. Epub 2017 Jan 26.

4.

NAD+ Kinase as a Therapeutic Target in Cancer.

Tedeschi PM, Bansal N, Kerrigan JE, Abali EE, Scotto KW, Bertino JR.

Clin Cancer Res. 2016 Nov 1;22(21):5189-5195. Epub 2016 Aug 31. Review.

5.

Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy.

Tedeschi PM, Lin H, Gounder M, Kerrigan JE, Abali EE, Scotto K, Bertino JR.

Mol Pharmacol. 2015 Oct;88(4):720-7. doi: 10.1124/mol.114.096727. Epub 2015 Jul 28.

6.

Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development.

Tedeschi PM, Vazquez A, Kerrigan JE, Bertino JR.

Mol Cancer Res. 2015 Oct;13(10):1361-6. doi: 10.1158/1541-7786.MCR-15-0117. Epub 2015 Jun 22.

7.

Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase.

Wu TJ, Wang X, Zhang Y, Meng L, Kerrigan JE, Burley SK, Zheng XF.

Cell Rep. 2015 Apr 21;11(3):446-59. doi: 10.1016/j.celrep.2015.03.040. Epub 2015 Apr 9.

8.

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.

Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Oncotarget. 2014 Feb 28;5(4):901-7.

9.

RNase H: specificity, mechanisms of action, and antiviral target.

Moelling K, Broecker F, Kerrigan JE.

Methods Mol Biol. 2014;1087:71-84. doi: 10.1007/978-1-62703-670-2_7.

PMID:
24158815
10.

Enterococcal and streptococcal resistance to PC190723 and related compounds: molecular insights from a FtsZ mutational analysis.

Kaul M, Zhang Y, Parhi AK, Lavoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS.

Biochimie. 2013 Oct;95(10):1880-7. doi: 10.1016/j.biochi.2013.06.010. Epub 2013 Jun 25.

11.

Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.

Xie X, Kerrigan JE, Minko T, Garbuzenko O, Lee KC, Scarborough A, Abali EE, Budak-Alpdogan T, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Cancer Biol Ther. 2013 Aug;14(8):742-51. doi: 10.4161/cbt.25184. Epub 2013 Jun 3.

12.

Molecular dynamics simulations in drug design.

Kerrigan JE.

Methods Mol Biol. 2013;993:95-113. doi: 10.1007/978-1-62703-342-8_7. Review.

PMID:
23568466
13.

Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction.

Hu L, Magesh S, Chen L, Wang L, Lewis TA, Chen Y, Khodier C, Inoyama D, Beamer LJ, Emge TJ, Shen J, Kerrigan JE, Kong AN, Dandapani S, Palmer M, Schreiber SL, Munoz B.

Bioorg Med Chem Lett. 2013 May 15;23(10):3039-43. doi: 10.1016/j.bmcl.2013.03.013. Epub 2013 Mar 14.

14.

Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.

Hsieh YC, Tedeschi P, Adebisi Lawal R, Banerjee D, Scotto K, Kerrigan JE, Lee KC, Johnson-Farley N, Bertino JR, Abali EE.

Mol Pharmacol. 2013 Feb;83(2):339-53. doi: 10.1124/mol.112.080218. Epub 2012 Nov 29.

15.

A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.

Kaul M, Parhi AK, Zhang Y, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS.

J Med Chem. 2012 Nov 26;55(22):10160-76. doi: 10.1021/jm3012728. Epub 2012 Oct 26.

16.

A second target of benzamide riboside: dihydrofolate reductase.

Roussel B, Johnson-Farley N, Kerrigan JE, Scotto KW, Banerjee D, Felczak K, Pankiewicz KW, Gounder M, Lin H, Abali EE, Bertino JR.

Cancer Biol Ther. 2012 Nov;13(13):1290-8. doi: 10.4161/cbt.21786. Epub 2012 Sep 6.

17.

High tolerance to mutations in a Chlamydia trachomatis peptide deformylase loop.

Oey CB, Bao X, Lewis C, Kerrigan JE, Fan H.

World J Biol Chem. 2011 May 26;2(5):90-7. doi: 10.4331/wjbc.v2.i5.90.

18.

Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes.

Mehta MS, Vazquez A, Kulkarni DA, Kerrigan JE, Atwal G, Metsugi S, Toppmeyer DL, Levine AJ, Hirshfield KM.

Breast Cancer Res Treat. 2011 Feb;125(3):861-8. doi: 10.1007/s10549-010-1062-1. Epub 2010 Jul 25.

19.

A G-quadruplex stabilizer induces M-phase cell cycle arrest.

Tsai YC, Qi H, Lin CP, Lin RK, Kerrigan JE, Rzuczek SG, LaVoie EJ, Rice JE, Pilch DS, Lyu YL, Liu LF.

J Biol Chem. 2009 Aug 21;284(34):22535-43. doi: 10.1074/jbc.M109.020230. Epub 2009 Jun 16.

20.

Modeling and biochemical analysis of the activity of antibiofilm agent Dispersin B.

Kerrigan JE, Ragunath C, Kandra L, Gyémánt G, Lipták A, Jánossy L, Kaplan JB, Ramasubbu N.

Acta Biol Hung. 2008 Dec;59(4):439-51. doi: 10.1556/ABiol.59.2008.4.5.

21.

Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.

Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF.

Cancer Res. 2007 Sep 15;67(18):8839-46.

23.
24.

Follitropin receptors contain cryptic ligand binding sites.

Lin W, Bernard MP, Cao D, Myers RV, Kerrigan JE, Moyle WR.

Mol Cell Endocrinol. 2007 Jan 2;260-262:83-92. Epub 2006 Oct 23.

25.

Synthesis and G-quadruplex stabilizing properties of a series of oxazole-containing macrocycles.

Minhas GS, Pilch DS, Kerrigan JE, LaVoie EJ, Rice JE.

Bioorg Med Chem Lett. 2006 Aug 1;16(15):3891-5. Epub 2006 Jun 2.

PMID:
16735121
26.

Models of glycoprotein hormone receptor interaction.

Moyle WR, Lin W, Myers RV, Cao D, Kerrigan JE, Bernard MP.

Endocrine. 2005 Apr;26(3):189-205. Review.

PMID:
16034173
27.

Design and construction of a phosphorylatable chimeric monoclonal antibody with a highly stable phosphate.

Wu W, Kerrigan JE, Yadav P, Schwartz B, Izotova L, Lavoie TB, Pestka S.

Oncol Res. 2004;14(11-12):541-58.

PMID:
15666996
28.

Model of glycoprotein hormone receptor ligand binding and signaling.

Moyle WR, Xing Y, Lin W, Cao D, Myers RV, Kerrigan JE, Bernard MP.

J Biol Chem. 2004 Oct 22;279(43):44442-59. Epub 2004 Aug 9.

29.
30.
31.

Thermodynamics of aminoglycoside-rRNA recognition.

Pilch DS, Kaul M, Barbieri CM, Kerrigan JE.

Biopolymers. 2003 Sep;70(1):58-79. Review.

PMID:
12925993
33.
35.

6-Acylamino-2-[(alkylsulfonyl)oxy]-1H-isoindole-1,3-dione mechanism-based inhibitors of human leukocyte elastase.

Kerrigan JE, Walters MC, Forrester KJ, Crowder JB, Christopher LJ.

Bioorg Med Chem Lett. 2000 Jan 3;10(1):27-30.

PMID:
10636236
36.

Anti-Pneumocystis activities of aromatic diamidoxime prodrugs.

Hall JE, Kerrigan JE, Ramachandran K, Bender BC, Stanko JP, Jones SK, Patrick DA, Tidwell RR.

Antimicrob Agents Chemother. 1998 Mar;42(3):666-74.

37.

4-Chloro-7-(iodoacetyl)amino-3-methoxy-isocoumarin.

Kerrigan JE, Powers JC, VanDerveer D.

Acta Crystallogr C. 1996 Feb 15;52 ( Pt 2):451-3.

PMID:
8829362
39.
40.
41.

Proteinase 3: substrate specificity and possible pathogenetic effect of Wegener's granulomatosis autoantibodies (c-ANCA) by dysregulation of the enzyme.

Dolman KM, van de Wiel BA, Kam CM, Kerrigan JE, Hack CE, von dem Borne AE, Powers JC, Goldschmeding R.

Adv Exp Med Biol. 1993;336:55-60.

PMID:
8296674
42.

Substrate and inhibitor studies on proteinase 3.

Kam CM, Kerrigan JE, Dolman KM, Goldschmeding R, Von dem Borne AE, Powers JC.

FEBS Lett. 1992 Feb 3;297(1-2):119-23.

Supplemental Content

Loading ...
Support Center